Inflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantation

Table 1 Clinical parameters of the study population n (%)

Parameter	Value
Mean age (yr)1	51.9 ± 6.9
Male	184 (82.1)
Diagnosis
Hepatitis B	197 (87.9)
Hepatitis C	13 (5.8)
Others	14 (6.3)
GRWR1	1.21 ± 0.27
Child pugh score1	8.2 ± 2.4
MELD score1	12.8 ± 7.6
AFP (ng/mL)1	183.4 ± 762.7
PIVKA-II (mAU/mL)1	206.5 ± 1118.7
C-reactive protein (mg/dL)1	1.36 ± 2.74
Neutrophil lymphocyte ratio1	3.47 ± 4.68
Pretransplant treatment for HCC	167 (74.6)
Tumor number1	2.6 ± 2.4
Maximum tumor size (cm)1	3.2 ± 3.1
Microvascular invasion	44 (21.3)
Edmondson-steiner grade (III-IV)	81 (42.9)
Within the milan criteria	133 (59.4)
Follow-up duration (mo)1	48.9 ± 37.3
	(median: 68, range: 6-139)

¹Values shown are mean ± SD except where stated otherwise. GRWR: Graft-to-recipient body weight ratio; MELD: Model for end-stage liver disease; AFP: Alpha-fetoprotein; PIVKA-II: Proteins induced by vitamin K antagonism or absence-II; HCC: Hepatocellular carcinoma.